copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Infants diagnosed with certain risk conditions at ≤12 months of age are . . . In addition to the 3 doses of 13vPCV or 15vPCV routinely recommended for healthy non-Indigenous children <5 years of age, children ≤12 months of age with risk conditions for pneumococcal disease (see Table Risk conditions for pneumococcal vaccination and eligibility for NIP funding) are recommended to receive: an additional dose of a pneumococcal conjugate vaccine at 6 months of age a dose
Pneumococcal disease | The Australian Immunisation Handbook Pneumococcal disease disproportionately affects Aboriginal and Torres Strait Islander children and adults Pneumococcal disease is more common in people with certain risk conditions See Infographic Pneumococcal vaccination for all Australians Infographic Pneumococcal vaccination for children <5 years old Infographic
Immunisation for Aboriginal and Torres Strait Islander people The recommendations and funding for additional vaccines for Aboriginal and Torres Strait Islander peoples vary from state to state, based on the local disease burden Extra vaccinations are in addition to the routine vaccinations offered throughout life (pregnancy, children, adolescents, adults and seniors)
Immunisation recommendations for children in Australia An additional dose of 13vPCV at 6 months of age is recommended and NIP-funded for Aboriginal and Torres Strait Islander children living in the Northern Territory, Queensland, South Australia and Western Australia
Aboriginal and Torres Strait Islander peoples immunisation . . . For this reason, Aboriginal and Torres Strait Islander peoples are prioritised for additional protection through the funding of further vaccines on the National Immunisation Program (NIP) Variations to recommendations for additional vaccines vary from state to state, based on local disease burden
Table. Catch-up schedule for PCVs for Aboriginal and Torres Strait . . . Catch-up schedule for 13vPCV or 15vPCV for Aboriginal and Torres Strait Islander children living in NT, Qld, SA or WA ONLY, and children from all states territories with any medical condition(s) associated with an increased risk of invasive pneumococcal disease, aged
National Immunisation Program Schedule Aboriginal and Torres Strait Islander children require a fourth dose of pneumococcal vaccine (13vPCV) at 12-18 months of age for children living in high risk areas (Queensland, Northern Territory, Western Australia and South Australia) Contact your State or Territory Health Department for details
National Immunisation Program - Department of Health and Aged Care The exception to this is Aboriginal and Torres Strait Islander children living in NT, Qld, SA and WA and children with risk conditions who are recommended to have an additional dose of 13vPCV at 6 months of age The NIP funded pneumococcal vaccine eligibility from 1 July 2020 is set out in more detail in Table 1
Pneumococcal vaccinations in Australia: current recommendations and . . . For children with medical risk conditions and Aboriginal and Torres Strait Islander children in certain states and territories, four doses of a pneumococcal conjugate vaccine (13vPCV or 15vPCV) at 2, 4, 6 and 12 months of age (3+1 schedule) are recommended; only 13vPCV is funded through the NIP
Pneumococcal vaccination for all Australians | The Australian . . . Recommendations for pneumococcal vaccination for all AustraliansPneumococcal disease is a rare but serious condition that can cause significant illness, disability and death Universal childhood schedule: all non-Indigenous children, and Aboriginal and Torres Strait Islander children living in ACT, NSW, Tas and Vic, should receive 3 doses of 13vPCV * dose 1 at age 2 months, dose 2 at age 4